Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment symbols : Srpt save search
Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Published: 2024-01-16 (Crawled : 23:00) - biospace.com/
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: -1.19%
H: 1.04%
C: -0.02%
srp-9003 treatment therapeutics study
REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
Published: 2024-01-16 (Crawled : 20:00) - prnewswire.com
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: -0.49%
H: 3.17%
C: 1.94%
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: -7.15%
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -6.94%
rgx-314 aaviate positive treatment trial
FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy
Published: 2023-06-22 (Crawled : 18:00) - fda.gov
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: -3.2%
H: 0.03%
C: -4.89%
fda treatment duchenne therapy
Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy
Published: 2022-09-29 (Crawled : 14:00) - biospace.com/
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: 0.03%
H: 1.51%
C: -0.28%
srp-9001 treatment application license therapeutics duchenne
Sarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy
Published: 2022-09-06 (Crawled : 13:00) - globenewswire.com
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: -0.38%
H: 0.55%
C: -0.26%
srp-5051 treatment fda lifted therapeutics duchenne clinical hold
Sarepta Therapeutics’ Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy
Published: 2022-01-10 (Crawled : 18:00) - biospace.com/
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: -4.22%
H: 0.94%
C: -9.36%
gene therapy
Lysogene Announces First Patient in the United States Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis
Published: 2021-08-30 (Crawled : 08:00) - biospace.com/
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: -0.24%
H: 0.97%
C: -2.94%
treatment gene therapy therapy gene therapies
Lysogene Announces FDA Fast Track Designation for LYS-GM101 Gene Therapy for the Treatment of GM1 Gangliosidosis
Published: 2021-07-08 (Crawled : 20:00) - biospace.com/
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: -0.43%
H: 2.2%
C: 1.76%
treatment fda fda fast track fast track gene therapy therapy gene therapies fast track designation designation
Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus for a Gene Therapy Candidate for the Treatment of the Fragile X Syndrome
Published: 2021-06-11 (Crawled : 08:00) - biospace.com/
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: -0.86%
H: 0.91%
C: 0.0%
treatment gene therapy therapy license gene therapies syndros
Lysogene Announces First Patient Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis
Published: 2021-06-09 (Crawled : 18:00) - biospace.com/
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: -0.24%
H: 5.87%
C: 4.1%
treatment gene therapy therapy gene therapies
Sarepta Therapeutics’ Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001
Published: 2021-05-18 (Crawled : 17:00) - biospace.com/
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: 5.51%
H: 7.83%
C: 2.74%
treatment gene therapy therapy duchenne gene therapies
Sarepta Therapeutics’ Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta’s Commercial Process Material
Published: 2021-05-18 (Crawled : 13:00) - globenewswire.com
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: 5.51%
H: 7.83%
C: 2.74%
treatment gene therapy therapy duchenne gene therapies commercialization
Sarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of MOMENTUM Study for SRP-5051, Its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
Published: 2021-04-30 (Crawled : 22:00) - biospace.com/
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: -0.43%
H: 1.54%
C: -0.37%
treatment duchenne
Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration
Published: 2021-03-18 (Crawled : 21:00) - globenewswire.com
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: 3.51%
H: 0.05%
C: -3.81%
treatment gene therapy therapy gene therapies
FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation
Published: 2021-02-25 (Crawled : 16:36) - fda.gov
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: 0.73%
H: 2.11%
C: 1.39%
fda treatment duchenne approval fda approval rare
Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45
Published: 2021-02-25 (Crawled : 20:25) - globenewswire.com
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: 0.73%
H: 2.11%
C: 1.39%
treatment fda fda approval injection approval duchenne dmd
Sarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
Published: 2020-12-04 (Crawled : 21:06) - globenewswire.com
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
| Email alert
Add to watchlist
treatment duchenne
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.